FSHR and cancer: Several studies have demonstrated the expression of FSHR in extragonadal tissues (Kim et al. 2024) including normal secretory-phase endometrium and endometriotic lesions (Ponikwicka-Tyszko et al. 2016), myometrium (Stilley et al. 2014a, 2016), placenta, fallopian tube (Stilley et al. 2014a), cervix (Stilley et al. 2014a), human umbilical cord endothelial cells (Stilley et al., 2014b), bone osteoclasts (Sun et al. 2006; Zhu et al. 2012), adipose tissue (Liu et al. 2015, 2017), as well as in tumor endothelial cells of different human cancers and their metastases (Siraj et al. 2013).